» Articles » PMID: 24661924

Screening for Adrenal Suppression in Children with Inflammatory Bowel Disease Discontinuing Glucocorticoid Therapy

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2014 Mar 26
PMID 24661924
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pharmacological doses of corticoids may result in adrenal suppression but with individual sensitivity. In paediatric inflammatory bowel disease (IBD), glucocorticoids are needed in the majority of the patients but there are less studies related to tapering off the drugs. The objective of this study was to estimate the frequency of adrenal insufficiency in children with IBD that were at the end of their systemic glucocorticoid therapy course.

Methods: The study was a retrospective case series of 59 consecutive paediatric IBD patients (median age 14.1 years; Crohn's disease n = 22, ulcerative colitis n = 26, unclassified colitis n = 11) that were on oral prednisolone therapy about to be discontinued. The study patients were treated in a tertiary university hospital setting. Serum morning cortisol was measured with Immulite 2000 cortisol kit. Values < 20 nmol/l are undetectable and indicate adrenal suppression, values > 69 nmol/l are considered to represent normal basal secretion.

Results: The morning cortisol was below the reference range in 20% of the patients and undetectable in 10%. Low cortisol levels associated with higher daily glucocorticoid doses (median 7.2 mg/m(2) vs. 3.0 mg/m(2) in patients with normal cortisol levels, p < 0.05) and with the long duration of the treatment (median 11 months vs. 4 months, p < 0.05). Patients with undetectable cortisol levels recovered within few weeks (median 5.6 weeks).

Conclusions: In paediatric IBD prolonged courses of glucocorticoids are frequent due to the steroid-dependent nature of the disease in a considerable proportion of patients. Adrenal suppression may occur in at least one fifth of the patients despite slowly tapering off the glucocorticoids. Notably, this is based on a set of serum cortisol measurements by request of experienced clinicians. All paediatric IBD patients receiving conventional doses of oral glucocorticoids should be subjected to screening for adrenal suppression when anticipated discontinuation of the drug.

Citing Articles

Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group.

van Rheenen P, Kolho K, Russell R, Aloi M, Deganello A, Hussey S J Pediatr Gastroenterol Nutr. 2025; 80(2):374-393.

PMID: 39741383 PMC: 11788976. DOI: 10.1002/jpn3.12378.


Glucocorticoid treatment and adrenal suppression in children: current view and open issues.

Improda N, Chioma L, Capalbo D, Bizzarri C, Salerno M J Endocrinol Invest. 2024; 48(1):37-52.

PMID: 39352628 PMC: 11729088. DOI: 10.1007/s40618-024-02461-9.


Baseline and Peak Cortisol Response to the Low-Dose Short Synacthen Test Relates to Indication for Testing, Age, and Sex.

Park J, Titman A, Lancaster G, Selvarajah B, Collingwood C, Powell D J Endocr Soc. 2022; 6(6):bvac043.

PMID: 35506145 PMC: 9049111. DOI: 10.1210/jendso/bvac043.


Efficacy of single serum cortisol reading obtained between 9 AM and 10 AM as an index of adrenal function in children treated with glucocorticoids or synthetic adrenocorticotropic hormone.

Goto M, Shibata N, Hasegawa Y Clin Pediatr Endocrinol. 2016; 25(3):83-9.

PMID: 27507908 PMC: 4965507. DOI: 10.1297/cpe.25.83.


Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation.

Hasdemir B, Mhaske P, Paruthiyil S, Garnett E, Heyman M, Matloubian M Am J Physiol Regul Integr Comp Physiol. 2016; 310(11):R1244-57.

PMID: 27053649 PMC: 4935495. DOI: 10.1152/ajpregu.00445.2015.

References
1.
Vihinen M, Raivio T, Verkasalo M, Janne O, Kolho K . Circulating glucocorticoid bioactivity during peroral glucocorticoid treatment in children and adolescents with inflammatory bowel disease. J Clin Gastroenterol. 2008; 42(9):1017-24. DOI: 10.1097/MCG.0b013e3180ca9585. View

2.
Turner D, Levine A, Escher J, Griffiths A, Russell R, Dignass A . Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012; 55(3):340-61. DOI: 10.1097/MPG.0b013e3182662233. View

3.
Lehtinen P, Ashorn M, Iltanen S, Jauhola R, Jauhonen P, Kolho K . Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis. 2011; 17(8):1778-83. DOI: 10.1002/ibd.21550. View

4.
Desrame J, Sabate J, Agher R, Bremont C, Gaudric M, Couturier D . Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol. 2002; 97(7):1785-91. DOI: 10.1111/j.1572-0241.2002.05786.x. View

5.
Ahmet A, Kim H, Spier S . Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol. 2011; 7:13. PMC: 3177893. DOI: 10.1186/1710-1492-7-13. View